Literature DB >> 9682382

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus.

Z Moldoveanu1, L Love-Homan, W Q Huang, A M Krieg.   

Abstract

Bacterial DNA causes B cell proliferation, immunoglobulin secretion, and Th1-like cytokine secretion, due to unmethylated CpG dinucleotides in particular base contexts (CpG motifs), which are far more common in bacterial DNA than in vertebrate DNA. Synthetic oligodeoxynucleotides (ODN) containing CpG motifs also trigger immune activation, suggesting possible utility as vaccine enhancers. Mice systemically primed with formalin-inactivated influenza virus mixed with CpG ODN, generated virus-specific serum antibodies at titres approximately seven times higher than mice immunized without CpG; the titres were further increased following an identical second injection. To determine whether CpG could be absorbed through mucosae and enhance vaccination responses, mice were immunized intranasally (IN) with the same preparation of virus with or without CpG ODN or Escherichia coli DNA. Following IN immunization, CpG ODN or E. coli DNA promoted increased production of influenza-specific antibodies in serum, saliva and the genital tract, compared with the control groups. These studies indicate that stimulatory CpG ODN are promising new immune enhancers for vaccination applications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682382     DOI: 10.1016/s0264-410x(98)80122-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  61 in total

1.  Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection.

Authors:  D M Klinman; J Conover; C Coban
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 2.  The response of human B lymphocytes to oligodeoxynucleotides.

Authors:  H Liang; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Rescue of B cells from apoptosis by immune stimulatory CpG DNA.

Authors:  A M Krieg; A K Yi
Journal:  Springer Semin Immunopathol       Date:  2000

Review 4.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

5.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 6.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

7.  Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes.

Authors:  Malgorzata Gierynska; Uday Kumaraguru; Seong-Kug Eo; Sujin Lee; Arthur Krieg; Barry T Rouse
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 8.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

9.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 10.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.